Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Новые представления об этиопатогенезе атопического дерматита и тактике ведения больных
Новые представления об этиопатогенезе атопического дерматита и тактике ведения больных
Тамразова О.Б., Стадникова А.С. Новые представления об этиопатогенезе атопического дерматита и тактике ведения больных. Consilium Medicum. Педиатрия (Прил.). 2015; 1: 64–69.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
В статье рассмотрены этиопатогенетические особенности формирования атопического дерматита. Особое внимание уделено влиянию внешних факторов – обсуждаются гигиеническая, диетическая, загрязнения воздуха и генно-миграционная теории, также большая роль отводится нарушению кожного барьера и иммунопатологии. Исходя из перечисленных этиопатогенетических факторов, основными направлениями лечения пациентов с атопическим дерматитом являются устранение и ограничение воздействия провоцирующих факторов внешней среды, назначение противовоспалительных средств и восстановление кожного барьера.
Ключевые слова: атопический дерматит, этиопатогенез, дезлоратадин, метилпреднизолона ацепонат, Бепантен.
Key words: atopic dermatitis, etiopathogenesis, desloratadine, methylprednisolone aceponate, Bepanten.
Ключевые слова: атопический дерматит, этиопатогенез, дезлоратадин, метилпреднизолона ацепонат, Бепантен.
________________________________________________
Key words: atopic dermatitis, etiopathogenesis, desloratadine, methylprednisolone aceponate, Bepanten.
Полный текст
Список литературы
1. Baena-Cagnani CE, Serra H, Teijero A, Croce JS. Prevention of allergy and asthma. Clin Exp All Rev 2003; 3: 51–7.
2. Pawankar R, Canonica GW, Holgate ST, Lockey RF. WAO White Book on Allergy 2011–2012. Milwaukee, Wisconsin, USA. WAO, 2011. URL: http://www.worldallergy.org/UserFiles/file/WAO-White-Book-on-Allergy_web.pdf
3. Kamer B, Pasowska R, Dółka E et al. Prevalence of atopic dermatitis in infants during the first six months of life: authors’ observations. Postep Derm Alergol 2013; 30: 277–81.
4. Kanceljak-Macan B, Macan J, Plavec D et al. Allergic disorders of the respiratory system and skin as a public health problem. Lijec Vjesn 2003; 125 (3–4): 81–7.
5. Дети в России. 2009. Стат. сб. ЮНИСЕФ, Росстат. М.: ИИЦ «Статистика России», 2009. / Deti v Rossii. 2009. Stat. sb. IuNISEF, Rosstat. M.: IITs «Statistika Rossii», 2009. [in Russian]
6. Кубанова А.А., Лесная И.Н., Кубанов А.А. и др. Анализ эпидемиологической ситуации по заболеваемости инфекциями, передаваемыми половым путем, и дерматозами на территории Российской Федерации. Вестн. дерматологии и венерологии. 2010; 5: 4–21. / Kubanova A.A., Lesnaia I.N., Kubanov A.A. i dr. Analiz epidemiologicheskoi situatsii po zabolevaemosti infektsiiami, peredavaemymi polovym putem, i dermatozami na territorii Rossiiskoi Federatsii. Vestn. dermatologii i venerologii. 2010; 5: 4–21. [in Russian]
7. Danby S, Cork MY. A new anderstanding of atopic dermatitis: the role of epidermal barrier dysfunction and subclinical inflammation. J Clin Dermatol 2010; 1: 33–46.
8. Strachan DP. Allergy and family size: a riddle worth solving. Clin Exp Allergy 1997; 27: 235–6.
9. Alfvén T, Braun-Fahrländer C, Brunekreef B et al. PARSIFAL study group. Allergic diseases and atopic sensitization in children related to farming and anthroposophic lifestyle – the PARSIFAL study. Allergy 2006; 61: 414–21.
10. Lee SY, Kwon JW, Seo JH et al. Prevalence of atopy and allergic diseases in Korean children: associations with a farming environment and rural lifestyle. Int Arch Allergy Immunol 2012; 158: 168–74.
11. Gerrard JW, Geddes CA, Reggin PL et al. Serum IgE levels in white and Métis communities in Saskatchewan. Ann Allergy 1976; 37: 91–100.
12. Tricon S, Willers S, Smit HA et al. Nutrition and allergic disease. Clin Exp Allergy Rev 2006; 6: 117–88.
13. Zaknun D, Schroecksnadel S, Kurz K, Fuchs D. Potential role of antioxidant food supplements, preservatives and colorants in the pathogenesis of allergy and asthma. Int Arch Allergy Immunol 2012; 157: 113–24.
14. Wickens K, Barry D, Friezema A et al. Fast foods – are they a risk factor for asthma? Allergy 2005; 60: 1537–41.
15. Kim BJ, Hong SJ. Ambient air pollution and allergic diseases in children. Korean J Pedatr 2012; 55: 185–92.
16. Takizawa H. Impact of air pollution on allergic diseases. Korean J Intern Med 2011; 26: 262–73.
17. Lodovici M, Bigagli E. Oxidative stress and air pollution exposure. J Toxicol 2011; 2011: 487074.
18. Vergara C, Tsai YJ, Grant AV et al. Gene encoding Duffy antigen/receptor for chemokines is associated with asthma and IgE in three populations. Am J Respir Crit Care Med 2008; 178: 1017–22.
19. Rutkowski K, Sowa P, Rutkowska-Talipska J et al. Allergic diseases: the price of civilisational progress. Postepy Dermatol Alergol 2014; 31 (2): 77–83.
20. Sandford AJ, Shirakawa T, Moffatt MF et al. Location of atopy and beta subunit of high affinity (Fc epsilon RI) on chromosome 11q. Lancet 1993; 341: 332–4.
21. Imahara SD, O’Keefe GE. Genetic determinants of the inflammatory response. Curr Opin Crit Care 2004; 10 (5): 318–324.
22. Sajić D, Asiniwasis R. A Look at Epidermal Barrier Function in Atopic Dermatitis: Physiologic Lipid Replacement and the Role of Ceramide. URL: http://www.skintherapyletter.com/2012/17.7/2.html
23. Volz A, Konge BP, Compton JG et al. Physical mapping of a functional cluster of epidermal differentiation gens on chromosome 1q21. Genomics1993; 18 (1): 92–9.
24. Palmer K, Irvine A, Terron-Kwiatkows A, Zhao Y et al. Common less-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006; 38: 441–6.
25. Mischke D, Konge BP, Marcnholz I, Volz A. Genes encoding structural proteins of epidermal cornification and S100 calcium- binding proteins form a gene complex (“epidermal differentiation”) of human chromosome 1q21. Y Invest Dermatol 1996; 106: 989–92.
26. Kato A, Fukai K, Oiso N et al. Association of SPINK5 gene polymorphisms with atopic dermatitis in the Japanese population. Br J Dermatol 2003; 148: 665–9.
27. Tagami H, Kobayashi H, O’goshi K, Kikuchi K. Atopic xerosis: employment of noninvasive biophysical instrumentation for the functional analyses of the mildly abnormal stratum corneum and for the efficacy assessment of skin care products. J Cosmet Dermatol 2006; 5 (2): 140–9.
28. Brenninkmeijer EE, Spuls PI, Legierse CM et al. Clinical differences between atopic and atopiform dermatitis. J Am Acad Dermatol 2008; 58 (3): 407–14.
29. Tokura Y. Extrinsic and intrinsic types of atopic dermatitis. J Dermatol Sci 2010; 58 (1): 1–7.
30. Elias PM, Schmuth M. Abnormal skin barrier in the etiopathogenesis of atopic dermatitis. Curr Allergy Asthma Rep 2009; 9 (4): 265–72.
31. Elias PM. An Appropriate response to the black-box warning: corrective, barrier repair therapy in atopic dermatitis. Clin Med Dermatol 2009; 2: 1–3.
32. Wuthrich B, Schmid-Grendelmeier P. The atopic eczema/dermatitis syndrome. Epidemiology, natural course, and immunology of the IgE-associated (“extrinsic”) and the nonallergic (“intrinsic”) AEDS. J Invest Allergol Clin Immunol 2003; 13 (1): 1–5.
33. Halken S. Prevention of allergic disease in childhood: clinical and epidemiological aspects of primary and secondary allergy prevention. Pediatr Allergy Immunol 2004; 15 (Suppl. 16): 4–5: 9–32.
34. Тамразова О.Б. Патогенетическая терапия детей, страдающих тяжелыми формами атопического дерматита. РМЖ. Педиатрия. 2013; 2: 108–15. / Tamrazova O.B. Patogeneticheskaia terapiia detei, stradaiushchikh tiazhelymi formami atopicheskogo dermatita. RMZh. Pediatriia. 2013; 2: 108–15. [in Russian]
35. Кунгуров Н.В., Кохан М.М., Кениксфест Ю.В. и др. Применение антигистаминного препарата Эриус (дезлоратадин) в комплексной терапии хронических дерматозов. Аллергология. 2005; 3: 51–5. / Kungurov N.V., Kokhan M.M., Keniksfest Iu.V. i dr. Primenenie antigistaminnogo preparata Erius (dezloratadin) v kompleksnoi terapii khronicheskikh dermatozov. Allergologiia. 2005; 3: 51–5. [in Russian]
36. Геппе Н.А., Селиверстова Н.А., Утюшева М.Г. Эффективность применения дезлоратадина при атопическом дерматите у детей. Аллергология. 2005; 2: 9–11. / Geppe N.A., Seliverstova N.A., Utiusheva M.G. Effektivnost' primeneniia dezloratadina pri atopicheskom dermatite u detei. Allergologiia. 2005; 2: 9–11. [in Russian]
37. Гущин И.С., Порошина Ю.А., Микеладзе К.Р. и др. Противоаллергическое действие дезлоратадина и лоратадина в условиях in vivo у человека. Аллергология. 2004; 2: 10–5. / Gushchin I.S., Poroshina Iu.A., Mikeladze K.R. i dr. Protivoallergicheskoe deistvie dezloratadina i loratadina v usloviiakh in vivo u cheloveka. Allergologiia. 2004; 2: 10–5. [in Russian]
38. Berger WE. The safety and efficacy of desloratadine for the management of allergic disease. Drug Saf 2005; 28 (12): 1101–18.
39. Luger TA. Balancing efficacy and safety in the management of atopic dermatitis: the role of methylprednisolone aceponate. JEADV 2011; 25: 251–8.
40. Advantan, methylprednisolone aceponate, SmPC. Intendis GmbH, Max-Dohrn-Straße 10, 10589 Berlin, Germany. Approval code: G.ADV.09.2013.0003
41. Самгин М.А., Иванов О.Л., Монахов С.А. Адвантан в терапии воспалительных дерматозов. Рос. журн. кожных и венерических болезней. 2005; 2: 30–4. / Samgin M.A., Ivanov O.L., Monakhov S.A. Advantan v terapii vospalitel'nykh dermatozov. Ros. zhurn. kozhnykh i venericheskikh boleznei. 2005; 2: 30–4. [in Russian]
42. Кунгуров Н.В., Кохан М.М., Кениксфест Ю.В. и др. Различные лекарственные формы метилпреднизолона ацепоната в терапии больных аллергическими заболеваниями кожи. Вест. дерматологии и венерологии. 2013; 3: 138–50. / Kungurov N.V., Kokhan M.M., Keniksfest Yu.V. i dr. Razlichnye lekarstvennye formy metilprednizolona atseponata v terapii bol'nykh allergicheskimi zabolevaniyami kozhi. Vest. dermatologii i venerologii. 2013; 3: 138–50. [in Russian]
43. Mason JM, Carr J, Buckley C et al. Improved emollient use reduces atopic eczema symptoms and is cost neutral in infants: before-and-after evaluation of a multifaceted educational support programme. BMC Dermatol 2013; 13: 7. doi: 10.1186/1471-5945-13-7.
44. Hon KL, Ching GK, Leung TF et al. Estimating emollient usage in patients with eczema. Clin Exp Dermatol 2010; 35 (1): 22–6.
45. Chamlin SL, Kao J, Frieden IJ, Sheu MY et al. Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity. J Am Acad Dermatol 2002; 47 (2): 198–208.
46. Ebner F, Heller A, Rippke F, Tausch I. Topical use of dexpanthenol in skin disorders. Am J Clin Dermatol 2002; 3 (6): 427–33.
47. Gehring W, Gloor M. Effect of topically applied dexpanthenol on epidermal barrier function and stratum corneum hydration. Results of a human in vivo study. Arzneimittelforschung 2000; 50 (7): 659–63.
48. Proksch E, Nissen HP. Dexpanthenol enhances skin barrier repair and reduces inflammation. after sodium lauryl sulphate-induced irritation. J Dermatolog Treat 2002; 13 (4): 173–8.
2. Pawankar R, Canonica GW, Holgate ST, Lockey RF. WAO White Book on Allergy 2011–2012. Milwaukee, Wisconsin, USA. WAO, 2011. URL: http://www.worldallergy.org/UserFiles/file/WAO-White-Book-on-Allergy_web.pdf
3. Kamer B, Pasowska R, Dółka E et al. Prevalence of atopic dermatitis in infants during the first six months of life: authors’ observations. Postep Derm Alergol 2013; 30: 277–81.
4. Kanceljak-Macan B, Macan J, Plavec D et al. Allergic disorders of the respiratory system and skin as a public health problem. Lijec Vjesn 2003; 125 (3–4): 81–7.
5. Дети в России. 2009. Стат. сб. ЮНИСЕФ, Росстат. М.: ИИЦ «Статистика России», 2009. / Deti v Rossii. 2009. Stat. sb. IuNISEF, Rosstat. M.: IITs «Statistika Rossii», 2009. [in Russian]
6. Kubanova A.A., Lesnaia I.N., Kubanov A.A. i dr. Analiz epidemiologicheskoi situatsii po zabolevaemosti infektsiiami, peredavaemymi polovym putem, i dermatozami na territorii Rossiiskoi Federatsii. Vestn. dermatologii i venerologii. 2010; 5: 4–21. [in Russian]
7. Danby S, Cork MY. A new anderstanding of atopic dermatitis: the role of epidermal barrier dysfunction and subclinical inflammation. J Clin Dermatol 2010; 1: 33–46.
8. Strachan DP. Allergy and family size: a riddle worth solving. Clin Exp Allergy 1997; 27: 235–6.
9. Alfvén T, Braun-Fahrländer C, Brunekreef B et al. PARSIFAL study group. Allergic diseases and atopic sensitization in children related to farming and anthroposophic lifestyle – the PARSIFAL study. Allergy 2006; 61: 414–21.
10. Lee SY, Kwon JW, Seo JH et al. Prevalence of atopy and allergic diseases in Korean children: associations with a farming environment and rural lifestyle. Int Arch Allergy Immunol 2012; 158: 168–74.
11. Gerrard JW, Geddes CA, Reggin PL et al. Serum IgE levels in white and Métis communities in Saskatchewan. Ann Allergy 1976; 37: 91–100.
12. Tricon S, Willers S, Smit HA et al. Nutrition and allergic disease. Clin Exp Allergy Rev 2006; 6: 117–88.
13. Zaknun D, Schroecksnadel S, Kurz K, Fuchs D. Potential role of antioxidant food supplements, preservatives and colorants in the pathogenesis of allergy and asthma. Int Arch Allergy Immunol 2012; 157: 113–24.
14. Wickens K, Barry D, Friezema A et al. Fast foods – are they a risk factor for asthma? Allergy 2005; 60: 1537–41.
15. Kim BJ, Hong SJ. Ambient air pollution and allergic diseases in children. Korean J Pedatr 2012; 55: 185–92.
16. Takizawa H. Impact of air pollution on allergic diseases. Korean J Intern Med 2011; 26: 262–73.
17. Lodovici M, Bigagli E. Oxidative stress and air pollution exposure. J Toxicol 2011; 2011: 487074.
18. Vergara C, Tsai YJ, Grant AV et al. Gene encoding Duffy antigen/receptor for chemokines is associated with asthma and IgE in three populations. Am J Respir Crit Care Med 2008; 178: 1017–22.
19. Rutkowski K, Sowa P, Rutkowska-Talipska J et al. Allergic diseases: the price of civilisational progress. Postepy Dermatol Alergol 2014; 31 (2): 77–83.
20. Sandford AJ, Shirakawa T, Moffatt MF et al. Location of atopy and beta subunit of high affinity (Fc epsilon RI) on chromosome 11q. Lancet 1993; 341: 332–4.
21. Imahara SD, O’Keefe GE. Genetic determinants of the inflammatory response. Curr Opin Crit Care 2004; 10 (5): 318–324.
22. Sajić D, Asiniwasis R. A Look at Epidermal Barrier Function in Atopic Dermatitis: Physiologic Lipid Replacement and the Role of Ceramide. URL: http://www.skintherapyletter.com/2012/17.7/2.html
23. Volz A, Konge BP, Compton JG et al. Physical mapping of a functional cluster of epidermal differentiation gens on chromosome 1q21. Genomics1993; 18 (1): 92–9.
24. Palmer K, Irvine A, Terron-Kwiatkows A, Zhao Y et al. Common less-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006; 38: 441–6.
25. Mischke D, Konge BP, Marcnholz I, Volz A. Genes encoding structural proteins of epidermal cornification and S100 calcium- binding proteins form a gene complex (“epidermal differentiation”) of human chromosome 1q21. Y Invest Dermatol 1996; 106: 989–92.
26. Kato A, Fukai K, Oiso N et al. Association of SPINK5 gene polymorphisms with atopic dermatitis in the Japanese population. Br J Dermatol 2003; 148: 665–9.
27. Tagami H, Kobayashi H, O’goshi K, Kikuchi K. Atopic xerosis: employment of noninvasive biophysical instrumentation for the functional analyses of the mildly abnormal stratum corneum and for the efficacy assessment of skin care products. J Cosmet Dermatol 2006; 5 (2): 140–9.
28. Brenninkmeijer EE, Spuls PI, Legierse CM et al. Clinical differences between atopic and atopiform dermatitis. J Am Acad Dermatol 2008; 58 (3): 407–14.
29. Tokura Y. Extrinsic and intrinsic types of atopic dermatitis. J Dermatol Sci 2010; 58 (1): 1–7.
30. Elias PM, Schmuth M. Abnormal skin barrier in the etiopathogenesis of atopic dermatitis. Curr Allergy Asthma Rep 2009; 9 (4): 265–72.
31. Elias PM. An Appropriate response to the black-box warning: corrective, barrier repair therapy in atopic dermatitis. Clin Med Dermatol 2009; 2: 1–3.
32. Wuthrich B, Schmid-Grendelmeier P. The atopic eczema/dermatitis syndrome. Epidemiology, natural course, and immunology of the IgE-associated (“extrinsic”) and the nonallergic (“intrinsic”) AEDS. J Invest Allergol Clin Immunol 2003; 13 (1): 1–5.
33. Halken S. Prevention of allergic disease in childhood: clinical and epidemiological aspects of primary and secondary allergy prevention. Pediatr Allergy Immunol 2004; 15 (Suppl. 16): 4–5: 9–32.
34. Tamrazova O.B. Patogeneticheskaia terapiia detei, stradaiushchikh tiazhelymi formami atopicheskogo dermatita. RMZh. Pediatriia. 2013; 2: 108–15. [in Russian]
35. Kungurov N.V., Kokhan M.M., Keniksfest Iu.V. i dr. Primenenie antigistaminnogo preparata Erius (dezloratadin) v kompleksnoi terapii khronicheskikh dermatozov. Allergologiia. 2005; 3: 51–5. [in Russian]
36. Geppe N.A., Seliverstova N.A., Utiusheva M.G. Effektivnost' primeneniia dezloratadina pri atopicheskom dermatite u detei. Allergologiia. 2005; 2: 9–11. [in Russian]
37. Gushchin I.S., Poroshina Iu.A., Mikeladze K.R. i dr. Protivoallergicheskoe deistvie dezloratadina i loratadina v usloviiakh in vivo u cheloveka. Allergologiia. 2004; 2: 10–5. [in Russian]
38. Berger WE. The safety and efficacy of desloratadine for the management of allergic disease. Drug Saf 2005; 28 (12): 1101–18.
39. Luger TA. Balancing efficacy and safety in the management of atopic dermatitis: the role of methylprednisolone aceponate. JEADV 2011; 25: 251–8.
40. Advantan, methylprednisolone aceponate, SmPC. Intendis GmbH, Max-Dohrn-Straße 10, 10589 Berlin, Germany. Approval code: G.ADV.09.2013.0003
41. Samgin M.A., Ivanov O.L., Monakhov S.A. Advantan v terapii vospalitel'nykh dermatozov. Ros. zhurn. kozhnykh i venericheskikh boleznei. 2005; 2: 30–4. [in Russian]
42. Kungurov N.V., Kokhan M.M., Keniksfest Yu.V. i dr. Razlichnye lekarstvennye formy metilprednizolona atseponata v terapii bol'nykh allergicheskimi zabolevaniyami kozhi. Vest. dermatologii i venerologii. 2013; 3: 138–50. [in Russian]
43. Mason JM, Carr J, Buckley C et al. Improved emollient use reduces atopic eczema symptoms and is cost neutral in infants: before-and-after evaluation of a multifaceted educational support programme. BMC Dermatol 2013; 13: 7. doi: 10.1186/1471-5945-13-7.
44. Hon KL, Ching GK, Leung TF et al. Estimating emollient usage in patients with eczema. Clin Exp Dermatol 2010; 35 (1): 22–6.
45. Chamlin SL, Kao J, Frieden IJ, Sheu MY et al. Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity. J Am Acad Dermatol 2002; 47 (2): 198–208.
46. Ebner F, Heller A, Rippke F, Tausch I. Topical use of dexpanthenol in skin disorders. Am J Clin Dermatol 2002; 3 (6): 427–33.
47. Gehring W, Gloor M. Effect of topically applied dexpanthenol on epidermal barrier function and stratum corneum hydration. Results of a human in vivo study. Arzneimittelforschung 2000; 50 (7): 659–63.
48. Proksch E, Nissen HP. Dexpanthenol enhances skin barrier repair and reduces inflammation. after sodium lauryl sulphate-induced irritation. J Dermatolog Treat 2002; 13 (4): 173–8.
2. Pawankar R, Canonica GW, Holgate ST, Lockey RF. WAO White Book on Allergy 2011–2012. Milwaukee, Wisconsin, USA. WAO, 2011. URL: http://www.worldallergy.org/UserFiles/file/WAO-White-Book-on-Allergy_web.pdf
3. Kamer B, Pasowska R, Dółka E et al. Prevalence of atopic dermatitis in infants during the first six months of life: authors’ observations. Postep Derm Alergol 2013; 30: 277–81.
4. Kanceljak-Macan B, Macan J, Plavec D et al. Allergic disorders of the respiratory system and skin as a public health problem. Lijec Vjesn 2003; 125 (3–4): 81–7.
5. Дети в России. 2009. Стат. сб. ЮНИСЕФ, Росстат. М.: ИИЦ «Статистика России», 2009. / Deti v Rossii. 2009. Stat. sb. IuNISEF, Rosstat. M.: IITs «Statistika Rossii», 2009. [in Russian]
6. Кубанова А.А., Лесная И.Н., Кубанов А.А. и др. Анализ эпидемиологической ситуации по заболеваемости инфекциями, передаваемыми половым путем, и дерматозами на территории Российской Федерации. Вестн. дерматологии и венерологии. 2010; 5: 4–21. / Kubanova A.A., Lesnaia I.N., Kubanov A.A. i dr. Analiz epidemiologicheskoi situatsii po zabolevaemosti infektsiiami, peredavaemymi polovym putem, i dermatozami na territorii Rossiiskoi Federatsii. Vestn. dermatologii i venerologii. 2010; 5: 4–21. [in Russian]
7. Danby S, Cork MY. A new anderstanding of atopic dermatitis: the role of epidermal barrier dysfunction and subclinical inflammation. J Clin Dermatol 2010; 1: 33–46.
8. Strachan DP. Allergy and family size: a riddle worth solving. Clin Exp Allergy 1997; 27: 235–6.
9. Alfvén T, Braun-Fahrländer C, Brunekreef B et al. PARSIFAL study group. Allergic diseases and atopic sensitization in children related to farming and anthroposophic lifestyle – the PARSIFAL study. Allergy 2006; 61: 414–21.
10. Lee SY, Kwon JW, Seo JH et al. Prevalence of atopy and allergic diseases in Korean children: associations with a farming environment and rural lifestyle. Int Arch Allergy Immunol 2012; 158: 168–74.
11. Gerrard JW, Geddes CA, Reggin PL et al. Serum IgE levels in white and Métis communities in Saskatchewan. Ann Allergy 1976; 37: 91–100.
12. Tricon S, Willers S, Smit HA et al. Nutrition and allergic disease. Clin Exp Allergy Rev 2006; 6: 117–88.
13. Zaknun D, Schroecksnadel S, Kurz K, Fuchs D. Potential role of antioxidant food supplements, preservatives and colorants in the pathogenesis of allergy and asthma. Int Arch Allergy Immunol 2012; 157: 113–24.
14. Wickens K, Barry D, Friezema A et al. Fast foods – are they a risk factor for asthma? Allergy 2005; 60: 1537–41.
15. Kim BJ, Hong SJ. Ambient air pollution and allergic diseases in children. Korean J Pedatr 2012; 55: 185–92.
16. Takizawa H. Impact of air pollution on allergic diseases. Korean J Intern Med 2011; 26: 262–73.
17. Lodovici M, Bigagli E. Oxidative stress and air pollution exposure. J Toxicol 2011; 2011: 487074.
18. Vergara C, Tsai YJ, Grant AV et al. Gene encoding Duffy antigen/receptor for chemokines is associated with asthma and IgE in three populations. Am J Respir Crit Care Med 2008; 178: 1017–22.
19. Rutkowski K, Sowa P, Rutkowska-Talipska J et al. Allergic diseases: the price of civilisational progress. Postepy Dermatol Alergol 2014; 31 (2): 77–83.
20. Sandford AJ, Shirakawa T, Moffatt MF et al. Location of atopy and beta subunit of high affinity (Fc epsilon RI) on chromosome 11q. Lancet 1993; 341: 332–4.
21. Imahara SD, O’Keefe GE. Genetic determinants of the inflammatory response. Curr Opin Crit Care 2004; 10 (5): 318–324.
22. Sajić D, Asiniwasis R. A Look at Epidermal Barrier Function in Atopic Dermatitis: Physiologic Lipid Replacement and the Role of Ceramide. URL: http://www.skintherapyletter.com/2012/17.7/2.html
23. Volz A, Konge BP, Compton JG et al. Physical mapping of a functional cluster of epidermal differentiation gens on chromosome 1q21. Genomics1993; 18 (1): 92–9.
24. Palmer K, Irvine A, Terron-Kwiatkows A, Zhao Y et al. Common less-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006; 38: 441–6.
25. Mischke D, Konge BP, Marcnholz I, Volz A. Genes encoding structural proteins of epidermal cornification and S100 calcium- binding proteins form a gene complex (“epidermal differentiation”) of human chromosome 1q21. Y Invest Dermatol 1996; 106: 989–92.
26. Kato A, Fukai K, Oiso N et al. Association of SPINK5 gene polymorphisms with atopic dermatitis in the Japanese population. Br J Dermatol 2003; 148: 665–9.
27. Tagami H, Kobayashi H, O’goshi K, Kikuchi K. Atopic xerosis: employment of noninvasive biophysical instrumentation for the functional analyses of the mildly abnormal stratum corneum and for the efficacy assessment of skin care products. J Cosmet Dermatol 2006; 5 (2): 140–9.
28. Brenninkmeijer EE, Spuls PI, Legierse CM et al. Clinical differences between atopic and atopiform dermatitis. J Am Acad Dermatol 2008; 58 (3): 407–14.
29. Tokura Y. Extrinsic and intrinsic types of atopic dermatitis. J Dermatol Sci 2010; 58 (1): 1–7.
30. Elias PM, Schmuth M. Abnormal skin barrier in the etiopathogenesis of atopic dermatitis. Curr Allergy Asthma Rep 2009; 9 (4): 265–72.
31. Elias PM. An Appropriate response to the black-box warning: corrective, barrier repair therapy in atopic dermatitis. Clin Med Dermatol 2009; 2: 1–3.
32. Wuthrich B, Schmid-Grendelmeier P. The atopic eczema/dermatitis syndrome. Epidemiology, natural course, and immunology of the IgE-associated (“extrinsic”) and the nonallergic (“intrinsic”) AEDS. J Invest Allergol Clin Immunol 2003; 13 (1): 1–5.
33. Halken S. Prevention of allergic disease in childhood: clinical and epidemiological aspects of primary and secondary allergy prevention. Pediatr Allergy Immunol 2004; 15 (Suppl. 16): 4–5: 9–32.
34. Тамразова О.Б. Патогенетическая терапия детей, страдающих тяжелыми формами атопического дерматита. РМЖ. Педиатрия. 2013; 2: 108–15. / Tamrazova O.B. Patogeneticheskaia terapiia detei, stradaiushchikh tiazhelymi formami atopicheskogo dermatita. RMZh. Pediatriia. 2013; 2: 108–15. [in Russian]
35. Кунгуров Н.В., Кохан М.М., Кениксфест Ю.В. и др. Применение антигистаминного препарата Эриус (дезлоратадин) в комплексной терапии хронических дерматозов. Аллергология. 2005; 3: 51–5. / Kungurov N.V., Kokhan M.M., Keniksfest Iu.V. i dr. Primenenie antigistaminnogo preparata Erius (dezloratadin) v kompleksnoi terapii khronicheskikh dermatozov. Allergologiia. 2005; 3: 51–5. [in Russian]
36. Геппе Н.А., Селиверстова Н.А., Утюшева М.Г. Эффективность применения дезлоратадина при атопическом дерматите у детей. Аллергология. 2005; 2: 9–11. / Geppe N.A., Seliverstova N.A., Utiusheva M.G. Effektivnost' primeneniia dezloratadina pri atopicheskom dermatite u detei. Allergologiia. 2005; 2: 9–11. [in Russian]
37. Гущин И.С., Порошина Ю.А., Микеладзе К.Р. и др. Противоаллергическое действие дезлоратадина и лоратадина в условиях in vivo у человека. Аллергология. 2004; 2: 10–5. / Gushchin I.S., Poroshina Iu.A., Mikeladze K.R. i dr. Protivoallergicheskoe deistvie dezloratadina i loratadina v usloviiakh in vivo u cheloveka. Allergologiia. 2004; 2: 10–5. [in Russian]
38. Berger WE. The safety and efficacy of desloratadine for the management of allergic disease. Drug Saf 2005; 28 (12): 1101–18.
39. Luger TA. Balancing efficacy and safety in the management of atopic dermatitis: the role of methylprednisolone aceponate. JEADV 2011; 25: 251–8.
40. Advantan, methylprednisolone aceponate, SmPC. Intendis GmbH, Max-Dohrn-Straße 10, 10589 Berlin, Germany. Approval code: G.ADV.09.2013.0003
41. Самгин М.А., Иванов О.Л., Монахов С.А. Адвантан в терапии воспалительных дерматозов. Рос. журн. кожных и венерических болезней. 2005; 2: 30–4. / Samgin M.A., Ivanov O.L., Monakhov S.A. Advantan v terapii vospalitel'nykh dermatozov. Ros. zhurn. kozhnykh i venericheskikh boleznei. 2005; 2: 30–4. [in Russian]
42. Кунгуров Н.В., Кохан М.М., Кениксфест Ю.В. и др. Различные лекарственные формы метилпреднизолона ацепоната в терапии больных аллергическими заболеваниями кожи. Вест. дерматологии и венерологии. 2013; 3: 138–50. / Kungurov N.V., Kokhan M.M., Keniksfest Yu.V. i dr. Razlichnye lekarstvennye formy metilprednizolona atseponata v terapii bol'nykh allergicheskimi zabolevaniyami kozhi. Vest. dermatologii i venerologii. 2013; 3: 138–50. [in Russian]
43. Mason JM, Carr J, Buckley C et al. Improved emollient use reduces atopic eczema symptoms and is cost neutral in infants: before-and-after evaluation of a multifaceted educational support programme. BMC Dermatol 2013; 13: 7. doi: 10.1186/1471-5945-13-7.
44. Hon KL, Ching GK, Leung TF et al. Estimating emollient usage in patients with eczema. Clin Exp Dermatol 2010; 35 (1): 22–6.
45. Chamlin SL, Kao J, Frieden IJ, Sheu MY et al. Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity. J Am Acad Dermatol 2002; 47 (2): 198–208.
46. Ebner F, Heller A, Rippke F, Tausch I. Topical use of dexpanthenol in skin disorders. Am J Clin Dermatol 2002; 3 (6): 427–33.
47. Gehring W, Gloor M. Effect of topically applied dexpanthenol on epidermal barrier function and stratum corneum hydration. Results of a human in vivo study. Arzneimittelforschung 2000; 50 (7): 659–63.
48. Proksch E, Nissen HP. Dexpanthenol enhances skin barrier repair and reduces inflammation. after sodium lauryl sulphate-induced irritation. J Dermatolog Treat 2002; 13 (4): 173–8.
________________________________________________
2. Pawankar R, Canonica GW, Holgate ST, Lockey RF. WAO White Book on Allergy 2011–2012. Milwaukee, Wisconsin, USA. WAO, 2011. URL: http://www.worldallergy.org/UserFiles/file/WAO-White-Book-on-Allergy_web.pdf
3. Kamer B, Pasowska R, Dółka E et al. Prevalence of atopic dermatitis in infants during the first six months of life: authors’ observations. Postep Derm Alergol 2013; 30: 277–81.
4. Kanceljak-Macan B, Macan J, Plavec D et al. Allergic disorders of the respiratory system and skin as a public health problem. Lijec Vjesn 2003; 125 (3–4): 81–7.
5. Дети в России. 2009. Стат. сб. ЮНИСЕФ, Росстат. М.: ИИЦ «Статистика России», 2009. / Deti v Rossii. 2009. Stat. sb. IuNISEF, Rosstat. M.: IITs «Statistika Rossii», 2009. [in Russian]
6. Kubanova A.A., Lesnaia I.N., Kubanov A.A. i dr. Analiz epidemiologicheskoi situatsii po zabolevaemosti infektsiiami, peredavaemymi polovym putem, i dermatozami na territorii Rossiiskoi Federatsii. Vestn. dermatologii i venerologii. 2010; 5: 4–21. [in Russian]
7. Danby S, Cork MY. A new anderstanding of atopic dermatitis: the role of epidermal barrier dysfunction and subclinical inflammation. J Clin Dermatol 2010; 1: 33–46.
8. Strachan DP. Allergy and family size: a riddle worth solving. Clin Exp Allergy 1997; 27: 235–6.
9. Alfvén T, Braun-Fahrländer C, Brunekreef B et al. PARSIFAL study group. Allergic diseases and atopic sensitization in children related to farming and anthroposophic lifestyle – the PARSIFAL study. Allergy 2006; 61: 414–21.
10. Lee SY, Kwon JW, Seo JH et al. Prevalence of atopy and allergic diseases in Korean children: associations with a farming environment and rural lifestyle. Int Arch Allergy Immunol 2012; 158: 168–74.
11. Gerrard JW, Geddes CA, Reggin PL et al. Serum IgE levels in white and Métis communities in Saskatchewan. Ann Allergy 1976; 37: 91–100.
12. Tricon S, Willers S, Smit HA et al. Nutrition and allergic disease. Clin Exp Allergy Rev 2006; 6: 117–88.
13. Zaknun D, Schroecksnadel S, Kurz K, Fuchs D. Potential role of antioxidant food supplements, preservatives and colorants in the pathogenesis of allergy and asthma. Int Arch Allergy Immunol 2012; 157: 113–24.
14. Wickens K, Barry D, Friezema A et al. Fast foods – are they a risk factor for asthma? Allergy 2005; 60: 1537–41.
15. Kim BJ, Hong SJ. Ambient air pollution and allergic diseases in children. Korean J Pedatr 2012; 55: 185–92.
16. Takizawa H. Impact of air pollution on allergic diseases. Korean J Intern Med 2011; 26: 262–73.
17. Lodovici M, Bigagli E. Oxidative stress and air pollution exposure. J Toxicol 2011; 2011: 487074.
18. Vergara C, Tsai YJ, Grant AV et al. Gene encoding Duffy antigen/receptor for chemokines is associated with asthma and IgE in three populations. Am J Respir Crit Care Med 2008; 178: 1017–22.
19. Rutkowski K, Sowa P, Rutkowska-Talipska J et al. Allergic diseases: the price of civilisational progress. Postepy Dermatol Alergol 2014; 31 (2): 77–83.
20. Sandford AJ, Shirakawa T, Moffatt MF et al. Location of atopy and beta subunit of high affinity (Fc epsilon RI) on chromosome 11q. Lancet 1993; 341: 332–4.
21. Imahara SD, O’Keefe GE. Genetic determinants of the inflammatory response. Curr Opin Crit Care 2004; 10 (5): 318–324.
22. Sajić D, Asiniwasis R. A Look at Epidermal Barrier Function in Atopic Dermatitis: Physiologic Lipid Replacement and the Role of Ceramide. URL: http://www.skintherapyletter.com/2012/17.7/2.html
23. Volz A, Konge BP, Compton JG et al. Physical mapping of a functional cluster of epidermal differentiation gens on chromosome 1q21. Genomics1993; 18 (1): 92–9.
24. Palmer K, Irvine A, Terron-Kwiatkows A, Zhao Y et al. Common less-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006; 38: 441–6.
25. Mischke D, Konge BP, Marcnholz I, Volz A. Genes encoding structural proteins of epidermal cornification and S100 calcium- binding proteins form a gene complex (“epidermal differentiation”) of human chromosome 1q21. Y Invest Dermatol 1996; 106: 989–92.
26. Kato A, Fukai K, Oiso N et al. Association of SPINK5 gene polymorphisms with atopic dermatitis in the Japanese population. Br J Dermatol 2003; 148: 665–9.
27. Tagami H, Kobayashi H, O’goshi K, Kikuchi K. Atopic xerosis: employment of noninvasive biophysical instrumentation for the functional analyses of the mildly abnormal stratum corneum and for the efficacy assessment of skin care products. J Cosmet Dermatol 2006; 5 (2): 140–9.
28. Brenninkmeijer EE, Spuls PI, Legierse CM et al. Clinical differences between atopic and atopiform dermatitis. J Am Acad Dermatol 2008; 58 (3): 407–14.
29. Tokura Y. Extrinsic and intrinsic types of atopic dermatitis. J Dermatol Sci 2010; 58 (1): 1–7.
30. Elias PM, Schmuth M. Abnormal skin barrier in the etiopathogenesis of atopic dermatitis. Curr Allergy Asthma Rep 2009; 9 (4): 265–72.
31. Elias PM. An Appropriate response to the black-box warning: corrective, barrier repair therapy in atopic dermatitis. Clin Med Dermatol 2009; 2: 1–3.
32. Wuthrich B, Schmid-Grendelmeier P. The atopic eczema/dermatitis syndrome. Epidemiology, natural course, and immunology of the IgE-associated (“extrinsic”) and the nonallergic (“intrinsic”) AEDS. J Invest Allergol Clin Immunol 2003; 13 (1): 1–5.
33. Halken S. Prevention of allergic disease in childhood: clinical and epidemiological aspects of primary and secondary allergy prevention. Pediatr Allergy Immunol 2004; 15 (Suppl. 16): 4–5: 9–32.
34. Tamrazova O.B. Patogeneticheskaia terapiia detei, stradaiushchikh tiazhelymi formami atopicheskogo dermatita. RMZh. Pediatriia. 2013; 2: 108–15. [in Russian]
35. Kungurov N.V., Kokhan M.M., Keniksfest Iu.V. i dr. Primenenie antigistaminnogo preparata Erius (dezloratadin) v kompleksnoi terapii khronicheskikh dermatozov. Allergologiia. 2005; 3: 51–5. [in Russian]
36. Geppe N.A., Seliverstova N.A., Utiusheva M.G. Effektivnost' primeneniia dezloratadina pri atopicheskom dermatite u detei. Allergologiia. 2005; 2: 9–11. [in Russian]
37. Gushchin I.S., Poroshina Iu.A., Mikeladze K.R. i dr. Protivoallergicheskoe deistvie dezloratadina i loratadina v usloviiakh in vivo u cheloveka. Allergologiia. 2004; 2: 10–5. [in Russian]
38. Berger WE. The safety and efficacy of desloratadine for the management of allergic disease. Drug Saf 2005; 28 (12): 1101–18.
39. Luger TA. Balancing efficacy and safety in the management of atopic dermatitis: the role of methylprednisolone aceponate. JEADV 2011; 25: 251–8.
40. Advantan, methylprednisolone aceponate, SmPC. Intendis GmbH, Max-Dohrn-Straße 10, 10589 Berlin, Germany. Approval code: G.ADV.09.2013.0003
41. Samgin M.A., Ivanov O.L., Monakhov S.A. Advantan v terapii vospalitel'nykh dermatozov. Ros. zhurn. kozhnykh i venericheskikh boleznei. 2005; 2: 30–4. [in Russian]
42. Kungurov N.V., Kokhan M.M., Keniksfest Yu.V. i dr. Razlichnye lekarstvennye formy metilprednizolona atseponata v terapii bol'nykh allergicheskimi zabolevaniyami kozhi. Vest. dermatologii i venerologii. 2013; 3: 138–50. [in Russian]
43. Mason JM, Carr J, Buckley C et al. Improved emollient use reduces atopic eczema symptoms and is cost neutral in infants: before-and-after evaluation of a multifaceted educational support programme. BMC Dermatol 2013; 13: 7. doi: 10.1186/1471-5945-13-7.
44. Hon KL, Ching GK, Leung TF et al. Estimating emollient usage in patients with eczema. Clin Exp Dermatol 2010; 35 (1): 22–6.
45. Chamlin SL, Kao J, Frieden IJ, Sheu MY et al. Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity. J Am Acad Dermatol 2002; 47 (2): 198–208.
46. Ebner F, Heller A, Rippke F, Tausch I. Topical use of dexpanthenol in skin disorders. Am J Clin Dermatol 2002; 3 (6): 427–33.
47. Gehring W, Gloor M. Effect of topically applied dexpanthenol on epidermal barrier function and stratum corneum hydration. Results of a human in vivo study. Arzneimittelforschung 2000; 50 (7): 659–63.
48. Proksch E, Nissen HP. Dexpanthenol enhances skin barrier repair and reduces inflammation. after sodium lauryl sulphate-induced irritation. J Dermatolog Treat 2002; 13 (4): 173–8.
Авторы
О.Б.Тамразова*1, А.С.Стадникова2
1 ФГАОУ ВО Российский университет дружбы народов. 117198, Россия, Москва, ул. Миклухо-Маклая, д. 6;
2 ГБУЗ Московский научно-практический центр дерматовенерологии и косметологии Департамента здравоохранения г. Москвы. 119071, Россия, Москва, Ленинский пр., д. 17
*anait_tamrazova@mail.ru
1 People’s Friendship University of Russia. 117198, Russian Federation, Moscow, ul. Miklukho-Maklaya, d. 6;
2 Moscow Scientific and Practical Center of Dermatovenerology and Cosmetology of the Department of Health of Moscow. 119071, Russian Federation, Moscow, Leninskiy pr., d. 17
*anait_tamrazova@mail.ru
1 ФГАОУ ВО Российский университет дружбы народов. 117198, Россия, Москва, ул. Миклухо-Маклая, д. 6;
2 ГБУЗ Московский научно-практический центр дерматовенерологии и косметологии Департамента здравоохранения г. Москвы. 119071, Россия, Москва, Ленинский пр., д. 17
*anait_tamrazova@mail.ru
________________________________________________
1 People’s Friendship University of Russia. 117198, Russian Federation, Moscow, ul. Miklukho-Maklaya, d. 6;
2 Moscow Scientific and Practical Center of Dermatovenerology and Cosmetology of the Department of Health of Moscow. 119071, Russian Federation, Moscow, Leninskiy pr., d. 17
*anait_tamrazova@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.